attendees
as of 6 May 2020, 8:00AM (GMT+2)
from 82 countries
Join companies like...
20Med Therapeutics - Abbvie - Adjuvatis - Amgen - AstraZeneca - Calixar - Catalent - Dupont - Eli Lilly - EMD Serono - Fosun Pharma - Fresenius - Gilead - Menarini - Merck - Pfizer - Roche - Sanofi - Takeda - Teva - UCB - Vaxess
LoginCompany types
Why participate?
Find potential R&D collaborations or COVID-19 assets available for in-licensing/acquisition
Secure funding from new investors or find licensing partners for your portfolio
Connect with new partners to reinforce your supply chain or increase production capabilities
Identify partners with research solutions such as high throughput screening tools, clinical research capacity, animal models
Discover new diagnostics, biomarkers, adjuvants, carrier systems or technologies
Leverage your manufacturing capacity for COVID-19 solutions (vaccines, therapeutics or diagnostics)
Who should attend?
The event is targeting organisations that have an active program on COVID 19 OR organisations that can bring a capacity or a service to collaborate on an active COVID 19 program.
Members of a COVID 19 task force in a pharma company looking for research tools or solutions for scale up
BD or S&E from a pharma company looking for a COVID 19 asset
BD or S&E from a pharma company looking for a COVID 19 enabler…. E.g. adjuvant platform or delivery system
Scientists from pharm companies or biotechs looking for research solutions such as high throughput screening tools, clinical research capacity, animal models etc.
Biotechs that need financing or that want to out licence a program with COVID 19 potential
CMOs that have capacity that could be leveraged for COVID 19 (vaccines, therapeutics or diagnostics)
Industrial Supply chain professionals – they are finding it hard to mitigate supply chain risk in a world that is switching from a global supply chain to a world with borders, production and distribution issues
Diagnostic companies that need additional scale up capabilities to meet the demands for diagnostic tests – both Nucleic-acid amplification tests and serology tests
Investors or funders that want to target this area
